Calgary, Alberta (ots/PRNewswire) - The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that dosing has commenced in a Phase 1 PK study with lead drug ...
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System. The study, published in the June issue of the ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary immunodeficiencies that can be administered in one site, once a month (up to every four weeks) Shire plc (LSE: SHP, NASDAQ: SHPG) is launching a pediatric indication for HyQvia (Human ...
Düsseldorf (ots) - ImmunoQure AG, a German biotechnology company focused on the development of autoantibodies as therapeutics to treat common human diseases today announced the publication of data in the leading scientific journal Cell, demonstrating that such therapeutics can limit a variety of common human ...
London, England and Durban, South Africa (ots/PRNewswire) - ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) ...
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple ...
Melsungen/Johannesburg (ots) - On 30 June 2016, B. Braun Medical, the South African subsidiary of the German B. Braun Group, completed its acquisition of Dismed Pharmaceutical (Pty) Ltd and Dismed Criticare (Pty) Ltd, both out of business rescue. With over 600 employees in South Africa, B. Braun specialises in the ...
Takeda Pharmaceutical Company Limited
Osaka, Japan (ots/PRNewswire) - Takeda unveils new IBD Super Hero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD If someone with inflammatory bowel disease (IBD) was a Super Hero, what would that hero ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - An estimated 16 million people in the U.S. are diagnosed with dry eye disease - Xiidra is the first prescription eye drop FDA-approved to treat both the signs and symptoms of dry eye disease - U.S. launch of Xiidra planned for third quarter 2016 Shire plc (LSE: SHP, ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest ...
Toronto (ots/PRNewswire) - Last year, a randomized placebo-controlled pilot study using patented Vielight 810 Infrared (https://vielight.com/product/vielight-810/) and patent-pending Vielight Neuro (http://vielight.com/neuro-transcranial-intranasal-light/) wearable devices was conducted involving 19 patients affected by Alzheimer's disease or dementia. The findings ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The partnership covers potential new medicines for atopic dermatitis and psoriasis, two of ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of Prematurity - Top-line analysis of secondary endpoints showed clinically relevant effects on severe complications related to lung and brain damage - These data support further ...
London (ots/PRNewswire) - Norgine B.V. today announced that it has completed the divestment of its MENA operations and product rights for MOVICOL®, MOVIPREP®, KLEAN-PREP® and NORMACOL® in MENA to Acino. (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) Peter Stein, CEO at Norgine said: "The divestment ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announces the European Medicines Agency (EMA) marketing approval of the mylife(TM) YpsoPump® insulin pump for use with prefilled pump ...
Sunnyvale, California (ots/PRNewswire) - Next Generation "Smart" System Enables Clinicians to Provide Highly Precise Treatment, Efficiently, for More Patients, Every Day Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...
Sunnyvale, California (ots/PRNewswire) - Largest Ever Accuray Deal Will Provide More Cancer Patients in the United Kingdom (UK) Access to Advanced, Precise Radiation Treatments Accuray Incorporated (NASDAQ: ARAY) has a signed deal with NHS Supply Chain for seven TomoTherapy® Systems in a new partnership designed to provide clinicians and their patients with additional ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that Victoza® (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts: 293-OR, 240-OR Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that ...
Darmstadt, Germany (ots/PRNewswire) - - Agreement provides Merck with exclusive license to cognitive remediation training programs - HAPPYneuron will be available for inclusion in Merck's MSdialog platform for use with Rebif® (interferon beta-1a) Merck, a leading science and technology company, announced today that ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 185-OR and 187-OR Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented ...
Paris (ots/PRNewswire) - Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The U.S. Predictive Health Intelligence Environment (PHIE) database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined ...
New Orleans (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstracts 87-LB and 90-LB New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin degludec injection ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
London (ots/PRNewswire) - Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral ...
Brussels (ots/PRNewswire) - - Bimekizumab is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases[1],[2] - In this early proof of concept study, bimekizumab showed fast and sustained efficacy on disease ...
Brussels (ots/PRNewswire) - For medical and trade media only. New data highlight breadth of UCB's pioneering portfolio with four molecules across five indications: - An oral presentation of data from the two year C-EARLY(TM) Phase 3 study of Cimzia®, exploring different dosing strategies - Oral presentations from ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...